A new treatment being investigated for bipolar depression has failed to meet its main goal in a recent study.
The drug’s developer, Intra-Cellular Therapies, released the results of the study this week which showed that patients receiving the drug, lumateperona, as a stand-alone treatment did not show a significant improvement in symptoms compared to those taking a placebo.
The study included 554 patients and was at odds with a different global study which did show an improvement in the severity of depressive symptoms compared to a placebo.
Lumateperona is also being investigated as an add-on therapy to traditional bipolar treatments — lithium and valproate — and if the results are positive, the company could still pursue a marketing application for the drug.
Headquartered in New York City, Intra-Cellular specializes in central nervous system diseases. The company calls lumateperona a “first-in-class” molecule because it targets dopamine, glutamate and serotonin — three neurotransmitter pathways associated with severe mental illness. The company has also studied the drug as a treatment for schizophrenia.
Results from the most recent bipolar study sent shares for the company falling by 14%.
总部设在纽约市，细胞内专门研究中枢神经系统疾病。该公司称 luateperona 为“一流”分子，因为它的目标是多巴胺、谷氨酸和血清素——与严重精神疾病相关的三种神经递质途径。该公司还研究了该药物作为治疗精神分裂症的药物。